Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- azacitidine
- Inqovi (cedazuridine / decitabine)
Interactions between your drugs
azaCITIDine cedazuridine
Applies to: azacitidine, Inqovi (cedazuridine / decitabine)
Cedazuridine may increase the blood levels and effects of azaCITIDine. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
cedazuridine food
Applies to: Inqovi (cedazuridine / decitabine)
Food may affect the absorption of the cancer drug (decitabine) in this medication. You should avoid eating for 2 hours before and 2 hours after taking cedazuridine-decitabine.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
DNA methyltransferase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'DNA methyltransferase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'DNA methyltransferase inhibitors' category:
- azacitidine
- Inqovi (cedazuridine / decitabine)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Reblozyl
Reblozyl is used to treat anemia in adults with beta-thalassemia or myelodysplastic syndromes ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Dacogen
Dacogen (decitabine) is used to treat myelodysplastic syndromes (certain types of blood or bone ...
Inqovi
Inqovi (decitabine and cedazuridine) is used for the treatment of myelodysplastic syndromes (MDS) ...
Rytelo
Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Decitabine
Decitabine is used for acute myeloid leukemia, myelodysplastic syndrome
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.